Geron Newswire

Comprehensive Real-Time News Feed for Geron.

Results 1 - 20 of 141 in Geron

  1. Geron's (GERN) CEO Dr. John Scarlett on Q4 2014 Results - Earnings Call TranscriptRead the original story w/Photo

    4 hrs ago | Seeking Alpha

    Good day, ladies and gentlemen. And welcome to the Q4 2014 Geron Earnings Conference Call.

    Comment?

  2. Geron (GERN) Q4 2014 Results - Earnings Call WebcastRead the original story w/Photo

    9 hrs ago | Seeking Alpha

    The following audio is from a conference call that will begin on March 03, 2015 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion.

    Comment?

  3. Geron Corporation Reports Fourth Quarter and Annual 2014 Financial Results and Recent EventsRead the original story

    10 hrs ago | PR-inside.com

    Organizational Resizing Also Announced Conference Call Scheduled for 4:30 p.m. EST Today, March 3 MENLO PARK, Calif., March 3, 2015 -- Geron Corporation today reported financial results for the fourth quarter and year ended December 31, 2014 and recent events. Fourth Quarter 2014 Results Net loss for the fourth quarter of 2014 was $8.9 million, or $0.06 per share, compared to $9.3 million, or $0.07 per share, for the comparable 2013 period.

    Comment?

  4. Ocata Therapeutics To Trade On Nasdaq Global Market: Can The Bulls Finally Rejoice?Read the original story w/Photo

    Thursday Feb 26 | Seeking Alpha

    ... frustration with Ocata's current market cap of approximately $211 million, as it pales to peer companies such as Geron (NASDAQ: GERN ) at $481 million, Pluristem Therapeutics (NASDAQ: PSTI ) at $216 million and Mesoblast Limited ( OTCPK:MBLTY ), ...

    Comment?

  5. Geron Corporation Announces Conference Call To Discuss Fourth Quarter ...Read the original story

    Wednesday Feb 25 | BioSpace

    Geron Corporation will announce its financial results for the fourth quarter and year ended December 31, 2014, on Tuesday, March 3, 2015, after the market close. Geron's management will also host a conference call for analysts and investors on Tuesday, March 3, 2015, at 4:30 p.m. Eastern Time to discuss the company's fourth quarter and annual results and recent events.

    Comment?

  6. Geron Announces Conference Call to Discuss Fourth Quarter and Annual...Read the original story

    Thursday Feb 26 | PR-inside.com

    Menlo Park, Calif., February 26, 2015 - Geron Corporation will announce its financial results for the fourth quarter and year ended December 31, 2014, on Tuesday, March 3, 2015, after the market close. Geron's management will also host a conference call for analysts and investors on Tuesday, March 3, 2015, at 4:30 p.m. Eastern Time to discuss the company's fourth quarter and annual results and recent events.

    Comment?

  7. Chiasma Inc. Appoints As Chairman Of The Board; Joins Board Of DirectorsRead the original story

    Monday Feb 23 | BioSpace

    ... and chairman of Pacira Pharmaceuticals, as chairman of the board and John "Chip" Scarlett, M.D., president and CEO of Geron Corporation, as a member of the board. "Chiasma will benefit from the deep experience and knowledge that Dave and Chip bring ...

    Comment?

  8. Chiasma Appoints David Stack as Chairman of the Board; John A....Read the original story

    Tuesday Feb 24 | Freshnews

    Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules its lead product for the orphan condition acromegaly, today announced the appointment of David Stack, president, CEO and chairman of Pacira Pharmaceuticals, as chairman of the board and John "Chip" Scarlett, M.D., president and CEO of Geron Corporation, as a member of the board. "Chiasma will benefit from the deep experience and knowledge that Dave and Chip bring to our board of directors," said Roni Mamluk, Ph.D., chief executive officer of Chiasma.

    Comment?

  9. Dr. Sergei Gryaznov: Geron Should Develop Imetelstat For ET/PVRead the original story w/Photo

    Thursday Feb 19 | Seeking Alpha

    Geron said in November that it will not develop Imet in ET after the FDA removed the clinical hold on the drug. The decision to re-initiate clinical trial in PV and ET lies with Janssen, which now has exclusive rights to Imet in all human therapeutic uses.

    Comment?

  10. Some Color On Geron's Presentation At The BIO ConferenceRead the original story w/Photo

    Tuesday Feb 10 | Seeking Alpha

    Geron presented at the BIO CEO and Investor Conference held in New York on February 10, 2015. Among the interesting things that CEO John Scarlett said was that Imetelstat is not an antisense molecule, which goes towards evidence of my idea in an earlier article that the '615 patent of December 2014, describing a molecule with antisense properties, is a step beyond Imetelstat.

    Comment?

  11. Geron Corporation To Present At The 17th Annual & Investor ConferenceRead the original story

    Sunday Feb 1 | BioSpace

    Geron Corporation today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 17th Annual BIO CEO & Investor Conference in New York. The presentation is scheduled to occur on Monday, February 9, at 2:00 p.m. Eastern Time.

    Comment?

  12. Geron to Present at the 17th Annual Bio Ceo & Investor ConferenceRead the original story

    Monday Feb 2 | PR-inside.com

    MENLO PARK, Calif., February 2, 2015 - Geron Corporation today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 17 Annual BIO CEO & Investor Conference in New York. The presentation is scheduled to occur on Monday, February 9, at 2:00 p.m. Eastern Time.

    Comment?

  13. 30 Reasons I Like GeronRead the original story w/Photo

    Jan 27, 2015 | Seeking Alpha

    A substantial part of my portfolio is devoted to Geron . For almost a year now, I have been writing about the company on Seeking Alpha - I have followed the telomerase technology off and on since the 2009 Nobel Prize.

    Comment?

  14. Has Geron Undersold Itself To Janssen?Read the original story w/Photo

    Jan 19, 2015 | Seeking Alpha

    For the last few months, I have been very bullish on Geron . My readers know that.

    Comment?

  15. It's Time To Invest In Geron: Johnson & Johnson Thinks SoRead the original story w/Photo

    Jan 13, 2015 | Seeking Alpha

    The current enterprise value of ~$368M leaves Geron arguably the cheapest stock on Wall Street with a billion dollar pharmaceutical drug deal. Those investors that follow my articles know that I like to write about biotechnology stocks that are currently undervalued with significant upcoming catalysts which have a high chance of success.

    Comment?

  16. It's Time To Invest In Geron: Johnson & Johnson Thinks SoRead the original story w/Photo

    Jan 13, 2015 | Seeking Alpha

    The current enterprise value of ~$368M leaves Geron arguably the cheapest stock on Wall Street with a billion dollar pharmaceutical drug deal. Those investors that follow my articles know that I like to write about biotechnology stocks that are currently undervalued with significant upcoming catalysts which have a high chance of success.

    Comment?

  17. Geron Enters 2015 On A More Assured NoteRead the original story w/Photo

    Dec 18, 2014 | Seeking Alpha

    It has been a rollercoaster ride for Geron Corporation investors in 2014. In March, the FDA's decision to place a clinical hold on the company's essential thromobocythemia and multiple myeloma studies and a partial clinical hold on the then investigator-sponsored trial of imetelstat in myleofibrosis sparked a huge sell-off.

    Comment?

  18. Geron Enters 2015 On A More Assured NoteRead the original story w/Photo

    Dec 18, 2014 | Seeking Alpha

    It has been a rollercoaster ride for Geron Corporation investors in 2014. In March, the FDA's decision to place a clinical hold on the company's essential thromobocythemia and multiple myeloma studies and a partial clinical hold on the then investigator-sponsored trial of imetelstat in myleofibrosis sparked a huge sell-off.

    Comment?

  19. Geron Corporation Announces Early HSR Clearance For Global Strategic...Read the original story

    Dec 15, 2014 | BioSpace

    Geron Corporation announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Acts of 1976 in connection with the exclusive worldwide license and collaboration agreement executed by the company on November 13, 2014 with Janssen Biotech, Inc. to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate. With the early termination of the applicable waiting period under the HSR Act, the collaboration agreement with Janssen is effective as of December 15, 2014 and the $35 million initial payment under the collaboration agreement is due to the company.

    Comment?

  20. Geron Announces Early HSR Clearance for Global Strategic Collaboration with JanssenRead the original story

    Dec 16, 2014 | PR-inside.com

    Menlo Park, Calif., December 16, 2014 - Geron Corporation announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Acts of 1976 in connection with the exclusive worldwide license and collaboration agreement executed by the company on November 13, 2014 with Janssen Biotech, Inc. to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate. With the early termination of the applicable waiting period under the HSR Act, the collaboration agreement with Janssen is effective as of December 15, 2014 and the $35 million initial payment under the collaboration agreement is due to the company.

    Comment?